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Adsorption in sepsis. The pathophysiology of sepsis offers a ride (LPS), trigger a global response that involves both
highly complicated scenario. In sepsis, endotoxin or other cellular and humoral pathways with the generation of pro-
gram-positive–derived products induce a complex and dynamic inflammatory and anti-inflammatory mediators [5, 7, 8].cellular response, giving rise to several mediators known to be
These include a major group of middle molecular sizerelevant in the pathogenesis of septic shock such as specific
(5 to 30 kD) peptides, collectively called cytokines, phos-mediators, substances responsible for up- or down-regulation
of cytokine receptors and cytokine antagonists, inactivators of pholipase A2-dependent products such as platelet-acti-
translational or transductional pathways, and precursor mole- vating factor (PAF), leukotrienes, and thromboxanes,
cules. In this review, we delve into some new concepts stem- and complement-derived activated products such as C3a,ming up from the use of sorbents in continuous plasma filtra-
C5a, and their desarginated products. Other agentstion. Nonspecific simultaneous removal of several mediators
of the inflammatory cascade have led to improved outcomes play a role in the pathophysiology of sepsis such as sur-
in animal models of septic shock and to improved hemodynam- face-expressed and soluble adhesion molecules, kinins,
ics in a pilot clinical study. It seems of great importance to thrombin, myocardial depressant substance(s), b-endor-
explore all possible treatment techniques that may have a direct
phin, and heat shock proteins. In normal conditions, theimpact on circulating mediators of sepsis and that also may
biological activity of these mediators is under the controlinterfere with the imbalance between proinflammatory and
anti-inflammatory substances in the critically ill patient with of specific inhibitors that may act at different levels.
multiple organ failure. In this view, the application of sorbents In sepsis or systemic inflammatory response syndrome
appears to open new and interesting therapeutic options. The (SIRS), the homeostatic balance is altered, and a pro-search for innovative treatments specifically targeted to the
found disturbance of relative production of different me-special needs of the critically ill patients seems therefore more
diators may be observed. The pathogenesis of sepsisimportant than the attempt to adjust concepts and technologies
that are normally applied to patients with chronic renal failure. might therefore be described by a sudden and severe
imbalance of proinflammatory and anti-inflammatory
factors in the host. The concept of sepsis as a simply
Sepsis is the leading cause of acute renal failure (ARF) proinflammatory event has been consequently chal-
and mortality in intensive care units [1–3]. It generally lenged. Recent studies on knockout mice have shown
develops as a result of the host response to infection [4]. that deficiency of the gene encoding for intercellular
The pathogenesis of sepsis represents a complex mosaic adhesion molecule-1 renders mice resistant to the lethal
of interconnected events in respect to which therapeutic outcome of high-dose endotoxin shock [9]. In these con-
strategies remain elusive. Sepsis may be considered a ditions, cell-associated cytokines in peripheral blood
form of severe systemic inflammation caused by local mononuclear cells (PBMCs) are decreased, and the ca-
and systemic effects of circulating proinflammatory me- pacity of these cells to produce tumor necrosis factor-a
diators [5]. Although several therapeutic attempts have (TNF-a) and interleukin-1b (IL-1b) in vitro in response
targeted specific components in the proinflammatory to LPS is significantly reduced [7, 10]. Hyporespon-
septic cascade, no improvement in survival has been siveness is not only present in monocytes, but it occurs
obtained in large-scale clinical trials focusing on specific in whole blood [11] and is associated with increased
molecules [6]. Components of gram-negative bacteria plasma levels of IL-10 and prostaglandin E2, which are
cell wall, such as the lipid A-containing lipopolysaccha- known to inhibit the production of proinflammatory cy-
tokines [10]. Terms such as monocyte deactivation, im-
munoparalysis, or more simply cell hyporesponsivenessKey words: sorbent, cytokines, renal replacement therapy, plasma fil-
tration, inflammatory cascade. have been introduced in order to illustrate the incapacity
of cells to respond to LPS stimuli due to overproductionÓ 2000 by the International Society of Nephrology
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Fig. 1. Schematic representation of the clinical presentation and biologic counterparts occurring in the proinflammatory and anti-inflammatory
phases of sepsis.
of anti-inflammatory cytokines (Fig. 1) [7, 11–13]. All gentle ultrafiltration, CRRTs make it possible to control
therapies specifically devoted to sepsis have so far ob- fluid and electrolyte balance maintaining the patient in
tained frustrating results [6]. Liano et al prospectively steady hemodynamic conditions. Continuous fluid re-
observed that ARF in the intensive care unit occurs moval allows infusion of large amounts of fluids and
predominantly as part of a multiple organ failure, while ensures adequate caloric intake. In spite of these definite
isolated ARF is the usual presentation in non-intensive advantages, the role of CRRTs in the framework of
care unit patients [14]. Their study implied a higher mor- “blood purification” has been challenged, and it is some-
tality in critically patients who developed ARF, support- times considered of minimal or no clinical relevance
ing the concept of a direct effect of the ARF itself on [18, 19]. Nevertheless, the use of CRRTs is expanding,
the mortality. Nevertheless, not only should therapeutic and new potential advantages have been proposed.
strategies be applied to treat ARF itself, but any avail- The use of high permeability membranes in CRRTs
able technique should be involved in the possible preven- allows the removal of measurable quantities of cytokines,
tion of such derangement. This global approach probably although plasma levels seem to not be affected [19].
would help in modifying the course of the septic syn- The mechanism of cytokine removal from the circulation
drome, and it may have an impact on mortality of the seems to rely on filtration and membrane adsorption.
critically ill patients. Transport of sepsis-associated mediators across highly
permeable membranes may be largely unpredictable be-
cause of variable effects of filtration rates, molecularCONTINUOUS RENAL
REPLACEMENT THERAPIES interactions, presence of electric charges, hydrophilic or
hydrophobic sites on the membrane, and finally bindingCritically ill patients with ARF are preferably treated
to plasma proteins and/or acute phase reactants, as wellwith continuous renal replacement therapies (CRRTs)
as to cell receptors. The possible elimination of cytokine-[15, 16]. Conventional CRRTs such as hemofiltration
inducing compounds rather than the cytokines should(CVVH) or hemodiafiltration (CVVHDF) have allowed
also be considered when dealing with highly permeabletreatment of patients who could not be treated otherwise,
membranes. Hoffmann et al reported that hemofiltrationbecause of the remarkable hemodynamic instability and
the severe catabolic status [17]. Because of slow and may remove cardiotoxic compounds [20] and TNF-a–,
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Fig. 2. Molecular weights of compounds of interest in sepsis-associated ARF in respect to the cutoff of high-permeability synthetic membranes.
Fig. 3. Evolution of sorbents in extracorpo-
real therapies for acute and chronic renal
failure.
but not IL-6– or IL-1b–inducing compounds [21]. Figure branes used in CRRTs. Therefore, considering all of
the previously mentioned factors, it seems that highly2 summarizes the list of different mediators that are
known to be associated with sepsis. As can be seen, a permeable membranes may have a limited capacity of
removal for molecules involved in the pathogenesis oflarge part of these mediators has molecular weights
above the cutoff of highly permeable synthetic mem- sepsis. Because of the limited capacity of filtration and
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Table 1. The use of sorbents in clinical practice
Sorbent Type Modality Applications
Nonselective Charcoal
coated Hemoperfusion Poisoning
uncoated Hemodiafiltration Chronic renal failure
Uncharged resins (Amberlite XAD-7)
Selective Hydrophobic resins Coupled plasma filtration adsorption (CPFA) Rabdomiolysis, hepatic failure
Powdered sorbent Hemodiadsorption and regenerative HIV; drug overdose; hepatic
push-pull pheresis failure
Microphere-based detoxification system Regenerative push-pull pheresis Poisnoning, LDL apheresis
Engineered matrices: Polymyxin-B polystyrene-derivative fibers;
macroporous cellulosic beads;
Engineered matrices: polyethyleneimine macroporous cellulosic beads
the possible early saturation of the sites for adsorption, it is hardly considerable as a CRRT. Large amounts of
plasma substitutes and the evident cost implications may,is very unlikely to obtain significant variations in plasma
circulating levels of the substances involved in the sys- in fact, limit the application of these techniques in the
clinical stage. Furthermore, plasma filtration techniquestemic inflammatory syndrome.
may lead to unwanted losses of plasma constituents that
cannot be adequately replaced by substitution fluids.
INNOVATIVE TECHNIQUES IN CRRTS The combined requirements of a CRRT with high
Conventional CRRTs have gained increased popular- sieving capacity and possible selective removal of sepsis-
ity because of their ability to remove the excess fluid associated mediators seem to find an answer in the appli-
and sodium in septic patients. The efficiency in terms of cation of sorbents.
urea and other toxin removal is not questioned today.
Limitations seem to become evident for protein-bound
SORBENTS IN EXTRACORPOREAL THERAPIEScompounds or for solutes in the molecular range beyond
the membrane cutoff. In order to enhance the removal of The use of sorbents in extracorporeal therapies has
been applied to the management of both acute andseptic-associated mediators, two approaches have been
taken under consideration. In their original proposal, chronic renal failure (Fig. 3 and Table 1) [28]. Classically,
hemoperfusion (HP) has been described as a techniqueGrootendorst et al suggested that high-volume (100 L/
day) hemofiltration could remove myocardial depressant in which the sorbent was placed in direct contact with
blood in an extracorporeal circulation. More recently,factors and other sepsis mediators [22]. Some of these
mediators could be found in the ultrafiltrate extracted this technique and other techniques like apheresis have
witnessed intensive research. Sorbents may be of naturalfrom a pig model of septic shock. In a subsequent clinical
study, Bellomo et al confirmed this possibility, as evi- origin such as charcoal (mineral or vegetal) or synthetic
(different resins with covalently bound groups reactivedenced by a significant reduction in norepinephrine ad-
ministration in animals with septic shock [23]. with specific ligands). Sorbents have been applied in
different treatment modalities such as HP, HP coupledA different approach has been to use membranes with
larger pores and permeability characteristics superior to with hemodialysis (HPHD), double-chamber hemodia-
filtration (PFDsorb), or coupled plasma filtration-adsorp-those currently used in hemofiltration. Lee et al sug-
gested an increased survival in a porcine model of septic tion (CPFA; Fig. 4). HP has the advantage of a much
simpler circuit, but it requires a very biocompatible sor-shock and related it to a general effect of enhanced blood
purification [24]. Other authors have reported either in bent because of the direct contact with blood and with
blood cells in particular. Charcoal has a high adsorbinganimal [25] or human [26] studies improved survival
when using plasmapheresis. In vitro studies show that capacity, especially for low molecular weight waste prod-
ucts that accumulate during kidney or liver failure. Itsplasma filtration allows the removal of higher amounts
of proinflammatory cytokines such as TNF-a, IL-1b, and use in HP, however, requires a coating of the sorbent
surface to make it biocompatible. Coated charcoal, al-IL-8. Clearance and sieving coefficients of these cyto-
kines are significantly increased with “open” plasma fil- though biocompatible, has a remarkably reduced adsorp-
tive capacity because of the cutoff of the coating material.tration membranes in comparison to high-flux hemofil-
tration membranes [27]. Based on these considerations, More recently, synthetic polymers have been introduced
with remarkable capacity for adsorption. The size selec-it would appear of great interest to expand the use of
plasmapheresis in septic patient and to study its impact tivity is only offered by the size of the pores on the
surface of the granular elements and not by the materialon survival on a larger scale. However, plasmapheresis
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Fig. 4. Possible modes of application of sorbents. (Top) The sorbent unit is placed in series before the hemodiafilter. Blood comes in direct
contact with the sorbent, and high biocompatibility is required. The system is defined HPHD. (Middle) The sorbent unit is placed online in the
ultrafiltrate produced from an hemofilter. The hemofilter is placed in series with the hemodiafilter. The system is used for online hemodiafiltration
in chronic patients, and it is defined as paired filtration dialysis with sorbent (PFDsorb). (Bottom) The sorbent unit is placed online in the plasma
filtrate produced from a plasma filter. The plasma filter is placed in series with the hemodiafilter. The system is used for critically ill patients with
septic shock, and it is defined as coupled plasma filtration adsorption (CPFA).
Table 2. Plasma treatment in sepsis: Criteria to assess safety. In another technique using uncoated sorbents [detoxi-
fication plasma filtration (DTPF); HemoCleanse, Inc.,In vitro
• Absorption of proteins (e.g., coagulation factors) West Lafayette, IN, USA], a hemodiabsorption mecha-
• Adsorption of antibiotics nism is associated with a push-pull plasma filtration sys-• Activation of fluid phase systems (e.g., complement, coagulation,
tem (a suspension of powdered sorbents surrounding 0.5fibrinolysis, kinins)
• Toxicology tests micros plasma filter membranes). Bidirectional plasma
• Endotoxin content flow (at 80 to 100 mL/min) across the plasma filtration• Particulate release
membrane provides direct contact between plasma pro-• Pressure drop
• Biocompatibility tests (ISO 9000) teins and powdered sorbents, as well as clearance of
• Risk analysis of the circuit cytokines (TNF-a, IL-1b, and IL-6) [29].In vivo
There has been a widespread tendency to remove “bad• Mortality in control animals
factors” rather than to attempt to bring about a restora-
tion of balance of physiological factors. Often, too much
emphasis has been placed on individual markers. We
itself. Another approach consists of the use of sorbents suggest that treatments should focus more carefully on
in “uncoated” form. These, however, cannot be placed a “balancing hypothesis” trying to restore a correct equi-
in direct contact with whole blood, and they are used librium between immunologic suppression and activa-
for the treatment online of the ultrafiltrate or the plasma- tion.
filtrate [28]. In these systems, plasma or plasma water is This is particularly true when the converging concepts
separated from whole blood, and after passing through of plasma filtration coupled with adsorption are to be
the sorbent, they are reinfused into the blood circuit applied to the very complex scenario of severe sepsis
evolving in septic shock.reconstituting whole blood structure.
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Fig. 5. Adsorption capacity for tumor necrosis factor-a (TNF-a) of two different sorbents: (A) uncoated charcoal, and (B) hydrophobic resin.
The experimental conditions were as described in Tetta et al [27].
CONTINUOUS PLASMA importantly, when tested at different linear velocity of
the cross flow, the efficiency in removing cytokines isFILTRATION ADSORPTION
maintained in a wide range of flow rates. Increased crossContinuous plasma filtration adsorption (CPFA) is a
flow velocity may reduce the efficiency of the sorbent.modality of blood purification in which plasma is sepa-
In spite of that, the amount of cytokine removed inrated from whole blood and circulated in a sorbent car-
one passage is far above the overall amount of cytokinetridge. After the sorbent unit, plasma is returned to the
carried into the sorbent cartridge (calculated on the basisblood circuit, and the whole blood undergoes hemofil-
of the highest levels detected in the plasma and the bloodtration or hemodialysis.
flows utilized in CRRT) by the blood from septic patients
[27]. These studies also showed that for hydrophodicRationale
resins of a given particle and pore size the binding ofThe rationale consists in the attempt to achieve ade-
cytokines (TNF-a) occurs after prior adsorption of a2-quate removal of molecules that are not removed by
macroglobulin, the carrier of cytokines in plasma.other hemofiltration or hemodialysis techniques. The ra-
A major criticism may be raised concerning the re-tionale for exposing the plasma to the sorbent in a plasma
moval of beneficial substances or drugs by the mecha-
filtration system is to exclude the blood cells from the
nism of adsorption. By using the experimental conditions
contact with the sorbent and to reinfuse endogenous described in Tetta et al [27], we assessed the different
plasma after nonselective simultaneous removal of dif- adsorptive properties of a hydrophobic resin for the most
ferent sepsis-associated mediators without the need of commonly used antibiotics (Fig. 6). Except for Vancomy-
donor plasma. The main issue is concerning the sparing cin, where a modest removal can be observed, the levels
effect on endogenous plasma as compared with potential of other antibiotics such as Tobramycin or Amikacin
unwanted losses of autologous plasma compounds. tend to remain stable over time.
The interesting rationale for such application has stim-
ulated a series of in vitro studies [27] and in animals, Animal studies
specifically on a model of rabbit endotoxic shock [30]. Animal studies were performed in a rabbit model of
These studies also aimed at assessing safety (Table 2). septic shock [30]. The model consisted of a single intrave-
Various types of sorbents have been tested for this appli- nous injection of LPS. The dose was experimentally ad-
cation (Fig. 5). justed to determine a mortality of 80% of the control
animals at 72 hours. Coupled plasma filtration-adsorp-
In vitro studies tion resulted in a significant (P 5 0.0041) survival (85%)
In vitro studies demonstrated that removal rates for at 72 hours with respect to untreated control rabbits
different molecules may be very different according to injected with the same amount of LPS.
In the pathogenesis of gram-negative infections, thethe structure and nature of the used sorbent [27]. More
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Fig. 6. Adsorption studies of antibiotics. Five
hundred milliliters of plasma were added in
separate experiments with Tobramycin (Nebi-
cina, Eli Lilly), vancomycin (Vancocina, Eli
Lilly) and Amikacin (BB K8, Bristol-Myers
Squibb) in order to reach the therapeutic con-
centrations. Vues recorded before (r) and
after (j) the cartridge were determined for
tobramycin (A) and amikacin (C) using the
PFIA Abbott analyzer TDX (Abbott), and
for vancomycin (B) using the PFIA Abbott
analyzer Axsym. Concentration values (pre-,
post-, and percentage removal) for tobra-
mycin, vancomycin, and amikacin were as fol-
lows: 10,600 mg, 8823 mg, 17%; 9267 mg, 300
mg, 97%; and 9560 mg, 8260 mg, 10%. Other
agents (data not shown) such as gentamin and
teichoplanin were tested in the same experi-
mental conditions: The removal rates were 56
and 93%, respectively.
complex and dynamic host interaction involves the in- mediators could be linked in a cause-effect relationship
with improved survival in our experimental model wasflammatory cascade, complement activation, coagulation
suggested. Furthermore, the study provided the rationalecascade, and hemodynamic derangements. In the animal
for the application of this new method of blood purifica-model, improved survival was negatively correlated with
tion in septic patients undergoing CRRT [31, 32].the severity score, which included plasma LPS concentra-
tion, bioactive TNF, as well as mean arterial pressure Clinical trial
(MAP), base excess (BE), and white blood cell count
A prospective randomized crossover trial aimed at
(WBC). However, cumulative survival was not correlated comparing clinical and biological effects of CPFA versus
with the levels of circulating TNF. It must be emphasized CVVH in critically ill septic patients has recently been
that the overall net effect on survival could be due to concluded. Preliminary results were presented in ab-
the removal not only of the measured mediators, but stract form (abstract; Brendolan et al, J Am Soc Nephrol
also to many other mediators not monitored in our study. 9:A0655, 1998). The major findings can be summarized as
follows: restoration of cell responsiveness to exogenousThe possibility that simultaneous removal of different
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alysis in sepsis with acute renal failure. Kidney Int 56(Suppl 72):LPS after five hours of treatment in all patients; increased
S84–S87, 1999
systemic vascular resistances and significant reduction of 12. Volk HD, Reinke P, Krausch D, Zuckermann H, Asadullah
K, Mueller JM, Doecke WD, Kox WJ: Monocyte deactivation:the dose of norepinephrine required to maintain a stable
Rationale for a new therapeutic strategy in sepsis. Intensive Carehemodynamics in the patients (mean 30%). These data
Med 22:(Suppl 4):S474–S481, 1996
suggest the possibility that CPFA, as opposed to CVVH, 13. Brandtzaeg P, Osnes L, Ovstebo R, Joo GB, Westvik A-B,
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